Terns Pharmaceuticals Posts Disappointing Data From Oral GLP-1 Trial

Dow Jones

Oct 22

By Kelly Cloonan

Terns Pharmaceuticals' trial data from its oral GLP-1 treatment for obesity missed a high threshold for efficacy, safety and tolerability.

The biopharmaceutical company said Tuesday it will not advance the therapy, or make any further metabolic disease investments.

"The threshold for a truly differentiated oral GLP-1RA therapy -- one that delivers safety, tolerability and efficacy -- is high," Chief Executive Amy Burroughs said.

The treatment's recent Phase 2 topline 12-week results did not meet this threshold, Burroughs added.

The results showed a maximum placebo-adjusted weight loss of 4.6%. About 12% of patients discontinued treatment due to adverse events, the majority of which were gastrointestinal related, the company said.

Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participants during a post-treatment follow-up period, two of which were drug related, the company said.

Shares slid 13% to $7.10 in after-hours trading. The stock is up 47% this year through the market close.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

October 21, 2025 16:31 ET (20:31 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2577802153"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577802153\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577802153?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-22 04:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577802153","market":"fut","top_or_hot":-1,"title":"Terns Pharmaceuticals Posts Disappointing Data From Oral GLP-1 Trial","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Terns Pharmaceuticals' trial data from its oral GLP-1 treatment for obesity missed a high threshold for efficacy, safety and tolerability. \n</p>\n<p>\n  The biopharmaceutical company said Tuesday it will not advance the therapy, or make any further metabolic disease investments. \n</p>\n<p>\n  \"The threshold for a truly differentiated oral GLP-1RA therapy -- one that delivers safety, tolerability and efficacy -- is high,\" Chief Executive Amy Burroughs said. \n</p>\n<p>\n  The treatment's recent Phase 2 topline 12-week results did not meet this threshold, Burroughs added. \n</p>\n<p>\n  The results showed a maximum placebo-adjusted weight loss of 4.6%. About 12% of patients discontinued treatment due to adverse events, the majority of which were gastrointestinal related, the company said. \n</p>\n<p>\n  Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participants during a post-treatment follow-up period, two of which were drug related, the company said. \n</p>\n<p>\n  Shares slid 13% to $7.10 in after-hours trading. The stock is up 47% this year through the market close. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 21, 2025 16:31 ET (20:31 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Terns Pharmaceuticals Posts Disappointing Data From Oral GLP-1 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTerns Pharmaceuticals Posts Disappointing Data From Oral GLP-1 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-22 04:31</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Terns Pharmaceuticals' trial data from its oral GLP-1 treatment for obesity missed a high threshold for efficacy, safety and tolerability. \n</p>\n<p>\n  The biopharmaceutical company said Tuesday it will not advance the therapy, or make any further metabolic disease investments. \n</p>\n<p>\n  \"The threshold for a truly differentiated oral GLP-1RA therapy -- one that delivers safety, tolerability and efficacy -- is high,\" Chief Executive Amy Burroughs said. \n</p>\n<p>\n  The treatment's recent Phase 2 topline 12-week results did not meet this threshold, Burroughs added. \n</p>\n<p>\n  The results showed a maximum placebo-adjusted weight loss of 4.6%. About 12% of patients discontinued treatment due to adverse events, the majority of which were gastrointestinal related, the company said. \n</p>\n<p>\n  Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participants during a post-treatment follow-up period, two of which were drug related, the company said. \n</p>\n<p>\n  Shares slid 13% to $7.10 in after-hours trading. The stock is up 47% this year through the market close. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 21, 2025 16:31 ET (20:31 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4144","symbol_name":"石油与天然气的储存和运输","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2577802153","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577802153","pubTimestamp":1761078660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Terns Pharmaceuticals' trial data from its oral GLP-1 treatment for obesity missed a high threshold for efficacy, safety and tolerability.The biopharmaceutical company said Tuesday it will not advance the therapy, or make any further metabolic disease investments.\"The threshold for a truly differentiated oral GLP-1RA therapy -- one that delivers safety, tolerability and efficacy -- is high,\" Chief Executive Amy Burroughs said.The treatment's recent Phase 2 topline 12-week results did not meet this threshold, Burroughs added.The results showed a maximum placebo-adjusted weight loss of 4.6%. About 12% of patients discontinued treatment due to adverse events, the majority of which were gastrointestinal related, the company said.Shares slid 13% to $7.10 in after-hours trading. The stock is up 47% this year through the market close.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4144":"石油与天然气的储存和运输","GLP":"Global Partners Lp","TERN":"Terns Pharmaceuticals, Inc.","BK4007":"制药","BK4590":"PTP"},"translate_title":"Terns Pharmaceuticals公布口服GLP-1试验数据令人失望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLP":1.5,"TERN":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Terns Pharmaceuticals' trial data from its oral GLP-1 treatment for obesity missed a high threshold for efficacy, safety and tolerability. \n\n\n  The biopharmaceutical company said Tuesday it will not advance the therapy, or make any further metabolic disease investments. \n\n\n  \"The threshold for a truly differentiated oral GLP-1RA therapy -- one that delivers safety, tolerability and efficacy -- is high,\" Chief Executive Amy Burroughs said. \n\n\n  The treatment's recent Phase 2 topline 12-week results did not meet this threshold, Burroughs added. \n\n\n  The results showed a maximum placebo-adjusted weight loss of 4.6%. About 12% of patients discontinued treatment due to adverse events, the majority of which were gastrointestinal related, the company said. \n\n\n  Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participants during a post-treatment follow-up period, two of which were drug related, the company said. \n\n\n  Shares slid 13% to $7.10 in after-hours trading. The stock is up 47% this year through the market close. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 21, 2025 16:31 ET (20:31 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}